Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels

Background: Measurement of enoxaparin's anticoagulant activity has been limited to specialized coagulation laboratories and has been impractical for areas needing rapid results, such as during coronary angioplasty. A new point-of-care device, Rapidpoint® ENOX®, was recently developed to measure...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2003, Vol.112 (5), p.301-306
Main Authors: Saw, Jacqueline, Kereiakes, Dean J, Mahaffey, Kenneth W, Applegate, Robert J, Braden, Gregory A, Brent, Bruce N, Brodie, Bruce R, Groce, James B, Levine, Glenn N, Leya, Fred, Moliterno, David J
Format: Article
Language:English
Subjects:
Aged
Anti-Xa activity
Biological and medical sciences
Blood coagulation
Blood Coagulation Tests - instrumentation
Clinical Laboratory Techniques
Clotting time
Drug Monitoring - instrumentation
Drug Monitoring - methods
Enoxaparin
Enoxaparin - blood
Enoxaparin - therapeutic use
Equipment Design
Factor Xa Inhibitors
Female
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
Miscellaneous
Point-of-Care Systems
Public health. Hygiene
Public health. Hygiene-occupational medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Measurement of enoxaparin's anticoagulant activity has been limited to specialized coagulation laboratories and has been impractical for areas needing rapid results, such as during coronary angioplasty. A new point-of-care device, Rapidpoint® ENOX®, was recently developed to measure clotting times with enoxaparin use. Objectives: To correlate ENOX times with anti-Xa levels among patients receiving enoxaparin. Methods: A total of 166 patients receiving enoxaparin for the prevention of deep venous thrombosis or as treatment during acute coronary syndromes or angioplasty were prospectively studied. Citrated and non-citrated whole-blood (CWB and NCWB) samples were obtained at baseline and peak enoxaparin activity. ENOX times were measured with whole-blood, and the Stachrom® anti-Xa assay was performed on the plasma from the remainder of the samples. The Pearson correlation coefficient was used to assess the relationship between these two assays. Results: There was a strong linear correlation between the ENOX times and the anti-Xa activities for both CWB ( r=0.89, p
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2004.01.006